Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb

被引：0
|
作者：
Hamid, O. [1 ]
Ros, W. [2 ]
Thompson, J. A. [3 ]
Hu-Lieskovan, S. [4 ]
Eskens, F. A. L. M. [5 ]
Diab, A. [6 ]
Doi, T. [7 ]
Wasser, J. [8 ]
Spano, J-P. [9 ]
Rizvi, N. A. [10 ]
Angevin, E. [11 ]
Chiappori, A. [12 ]
Ott, P. A. [13 ]
Ganguly, B. J. [14 ]
Fleener, C. [15 ]
Dell, V. [16 ]
Liao, K. [16 ]
Joh, T. [16 ]
Chou, J. [17 ]
El-Khoueiry, A. [18 ]
机构：
[1] Angeles Clin & Res Inst, Med, Los Angeles, CA USA
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Univ Washington, Seattle Canc Care Alliance, Dept Med, Seattle, WA 98195 USA
[4] UCLA, Sch Med, Med, Los Angeles, CA USA
[5] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[6] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA
[7] Natl Canc Ctr Hosp East, Med Oncol, Chiba, Japan
[8] Neag Comprehens Canc Ctr, UConn Hlth, Div Hematol & Med Oncol, Farmington, CT USA
[9] Grp Hosp Pitie Salpetriere, Med Oncol, Paris, France
[10] Columbia Univ, Med, New York, NY USA
[11] Gustave Roussy Inst Cancerol, Med, Villejuif, France
[12] Univ S Florida, H Lee Moffitt Canc Ctr, Med, Tampa, FL USA
[13] Dana Farber Canc Inst, Med, Boston, MA 02115 USA
[14] Pfizer Inc, Early Oncol Dev & Clin Res, San Francisco, CA USA
[15] Pfizer Inc, Early Oncol Dev & Clin Res, Groton, CT 06340 USA
[16] Pfizer Inc, Early Oncol Dev & Clin Res, La Jolla, CA USA
[17] Pfizer, Res & Dev, San Francisco, CA USA
[18] Univ Southern Calif, Med, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1142PD
引用
收藏
页数：1
相关论文
共 12 条
  • [1] The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of 0X40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).
    El-Khoueiry, Anthony B.
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Ferry
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Chou, Jeffrey
    Liao, Ken
    Ganguly, Bishu J.
    Fleener, Catherine
    Joh, Tenshang
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600)
    Diab, Adi
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Fredericus A. L. M.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Long, Hua
    Joh, Tenshang
    Potluri, Shoba
    Wang, Xiao
    Fleener, Catherine
    Taylor, Carrie Turich
    Ganguli, Bishu J.
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] RESULTS FROM A COMBINATION OF OX40 (PF-04518600) AND 4-1BB (UTOMILUMAB) AGONISTIC ANTIBODIES IN MELANOMA AND NON-SMALL CELL LUNG CANCER IN A PHASE 1 DOSE EXPANSION COHORT
    Chiappori, Alberto
    Thompson, John
    Eskens, Fredericus
    Spano, Jean-Philippe
    Doi, Toshihiko
    Hamid, Omid
    Diab, Adi
    Rizvi, Naiyer
    Hu-Lieskovan, Siwen
    Ros, Willeke
    Thomas, Jacob
    Forgie, Alison
    Yang, Wenjing
    Liao, Ken
    Li, Ray
    Kazazi, Farhad
    Chou, Jeffrey
    El Khoueiry, Anthony
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A9 - A10
  • [4] Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)
    Hamid, O.
    Hu-Lieskovan, S.
    Ros, W.
    Diab, A.
    El-Khoueiry, A. B.
    Thompson, J. A.
    Eskens, F. A.
    Spano, J-P.
    Angevin, E.
    Rizvi, N. A.
    Wasser, J. S.
    Ott, P. A.
    Chiappori, A.
    Joh, T.
    Krupka, H. I.
    Potluri, S.
    Wang, X.
    Ganguli, B. J.
    Chou, J.
    Doi, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 422 - 422
  • [5] First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results
    Hamid, Omid
    Thompson, John A.
    Diab, Adi
    Ros, Willeke
    Eskens, Ferry
    Bermingham, Candy
    Konto, Cyril
    Long, Hua
    Liao, Ken
    Ganguly, Bishu J.
    Fleener, Catherine
    Pleasic-Williams, Susan
    Garzone, Pamela D.
    Patel, Premal H.
    Joh, Tenshang
    Nuyten, Dimitry S. A.
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies
    Knisely, Anne
    Ahmed, Jibran
    Stephen, Bettzy
    Piha-Paul, Sarina A.
    Karp, Daniel
    Zarifa, Abdulrazzak
    Fu, Siqing
    Hong, David Sanghyun
    Rodon Ahnert, Jordi
    Yap, Timothy A.
    Tsimberidou, Apostolia M.
    Alshawa, Anas
    Dumbrava, Ecaterina E.
    Yang, Yali
    Song, Juhee
    Meric-Bernstam, Funda
    Jazaeri, Amir A.
    Naing, Aung
    CANCER, 2024, 130 (03) : 400 - 409
  • [7] First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
    Hamid, Omid
    Chiappori, Alberto A.
    Thompson, John A.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Eskens, Ferry A. L. M.
    Ros, Willeke
    Diab, Adi
    Spano, Jean-Philippe
    Rizvi, Naiyer A.
    Wasser, Jeffrey S.
    Angevin, Eric
    Ott, Patrick A.
    Forgie, Alison
    Yang, Wenjing
    Guo, Cen
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [8] A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
    Calvo, Emiliano
    Moreno, Victor
    Perets, Ruth
    Yablonski-Peretz, Tamar
    Fourneau, Nele
    Girgis, Suzette
    Guo, Yue
    Hellemans, Peter
    Hokey, David
    Pendas Franco, Natalia
    Xia, Qi
    Geva, Ravit
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] A first-in-human, phase I, dose-escalation study to evaluate pharmacokinetics, safety, and tolerability of KD6001, a novel anti-CTLA-4 monoclonal antibody (mAb) in patients with advanced solid tumors
    Tang, Bixia
    Duan, Rong
    Li, Siming
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Mao, Lili
    Wang, Xuan
    Lian, Bin
    Wei, Xiaoting
    Yan, Xieqiao
    Li, Juan
    Zhou, Li
    Xu, Huayan
    Li, Caili
    Cai, Zeling
    Zhang, Chi
    Wang, Fangfang
    Guo, Jun
    Chi, Zhihong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.
    Naumovski, L.
    Gordon, M. S.
    Munster, P. N.
    Hegde, P.
    Fredrickson, J.
    Bai, S.
    Funke, R. P.
    Chang, I.
    Chandler, G. S.
    Chen, D. S.
    Rosen, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12